文献速递腹部技术与安全CT

急诊科口服对比剂给药的费用影响:时间驱动作业成本法分析

Cost Implications of Oral Contrast Administration in the Emergency Department: A Time-Driven Activity-Based Costing Analysis.
PubMed 文献 · J Am Coll Radiol · 2018-08-26

本研究在四级医疗中心采用时间驱动作业成本法,结合前瞻性时间研究与2016年1月1日至2016年12月31日的回顾性数据,量化急诊科非创伤性腹痛患者口服对比剂给药的金钱与时间成本,并评估放宽口服对比剂使用标准的政策变更带来的费用节约。基线口服对比剂使用率为86%(4541/5263),年基础成本估计为82,552美元,新政策使年成本降低52%(节约35,836.57美元)。作者结论认为急诊科口服对比剂相关成本适中,应与其潜在诊断获益相平衡。

要点

  • 基线口服对比剂使用率为86%(4541/5263),年基础成本估计为82,552美元。
  • 新政策(BMI≥25 kg/m²、CT前30天内无腹部手术、无炎症性肠病者免用口服对比剂)使年成本降低52%,节约35,836.57美元。
  • 模型对需要口服对比剂的CT检查量最为敏感,多因素分析中年成本范围为13,685至315,393美元。

核心结论

  • 急诊科口服对比剂相关成本适中,应与其潜在诊断获益相平衡;作者提出的标准使口服对比剂使用率降低52%。

研究设计与样本

  • 经机构审查委员会批准、符合HIPAA的时间驱动作业成本法分析,采用前瞻性时间研究和来自四级医疗中心的回顾性数据,回顾性数据覆盖2016年1月1日至2016年12月31日。

诊断标准与关键数值

  • 新政策免除口服对比剂的条件为:体重指数≥25 kg/m²、CT前30天内无腹部手术、无炎症性肠病。
  • 基线口服对比剂使用率为86%(4541/5263)。
  • 年基础成本估计为82,552美元,多因素分析范围为13,685至315,393美元。
  • 应用新政策参数使年成本降低52%,节约35,836.57美元。

临床应用与阅片要点

  • 作者提出的标准使口服对比剂使用率降低52%,年成本降低52%(节约35,836.57美元)。
  • 口服对比剂对出院时间的影响高度可变,取决于所用对比剂种类。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To quantify the monetary and time costs associated with oral contrast administration in the emergency department (ED) for patients with nontraumatic abdominal pain and to evaluate the cost savings associated with an institutional policy change in the criteria for oral contrast administration.

METHODS: A HIPAA-complaint, institutional review board-approved time-driven activity-based costing analysis was performed using both prospective time studies and retrospective data obtained from a quaternary care center. Retrospective data spanned a 1-year period (January 1, 2016, to December 31, 2016). A process map was generated. Examination volume-related data, labor costs, and material costs were determined and applied to a base-case model. Univariate and multivariate sensitivity analyses were conducted. Multivariate analysis was used to estimate the cost savings associated with a policy change eliminating oral contrast for patients with body mass index ≥ 25 kg/m2, no prior abdominal surgery within 30 days preceding CT, and no inflammatory bowel disease.

RESULTS: The baseline oral contrast utilization rate was 86% (4,541 of 5,263). The annual base-case cost estimate for oral contrast administration was $82,552. In multivariate analyses, this ranged from $13,685 to $315,393. The model was most sensitive to the volume of CTs requiring oral contrast. Applying parameters from the new policy change reduced the annual cost by 52% (cost saving: $35,836.57). Impact of oral contrast on time to discharge was highly variable and dependent on the contrast agent utilized.

CONCLUSION: Costs associated with oral contrast in the ED are modest and should be balanced with its potential diagnostic benefits. Our criteria reduced oral contrast utilization by 52%.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Shankar PR, Parikh KR, Heilbrun ME, et al. Cost Implications of Oral Contrast Administration in the Emergency Department: A Time-Driven Activity-Based Costing Analysis. J Am Coll Radiol. 2018. PMID: 30158081. doi:10.1016/j.jacr.2018.07.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。